You are viewing an obsolete version of the DU website which is no longer supported by the Administrators. Visit The New DU.
Democratic Underground Latest Greatest Lobby Journals Search Options Help Login
Google

Reply #50: Restatements Deliver Fuel for Reform [View All]

Printer-friendly format Printer-friendly format
Printer-friendly format Email this thread to a friend
Printer-friendly format Bookmark this thread
This topic is archived.
Home » Discuss » Latest Breaking News Donate to DU
54anickel Donating Member (1000+ posts) Send PM | Profile | Ignore Thu Apr-06-06 10:36 AM
Response to Reply #49
50. Restatements Deliver Fuel for Reform
Two restatements supply fodder for the case against providing Sarbox 404 regulatory breaks for diminuitive companies.

http://www.cfo.com/article.cfm/6768054/c_6771225?f=home_todayinfinance

Providing support for arguments against regulatory breaks for small caps, Richardson Electronics and Hemispherx Biopharma announced restatements stemming from accounting errors and saw their share prices dive.

Securities and Exchange Commission chairman Christopher Cox said earlier this week that small companies shouldn't necessarily expect a pass on complying with Section 404 of the Sarbanes-Oxley Act, which dictates stiff rules for assessing internal controls. Former SEC chairs Arthur Levitt, Richard Breeden, and Lynn Turner have already expressed their opposition to such exemptions.

On Wednesday, Richardson Electronics reported that it would recast its results for the three years ending in May 2005 as well as for the first two quarters of the current fiscal year. The $112 million market-cap electronics distributor made the announcement after it discovered errors in financial accounting at one of its Italian subsidiaries. Investors sliced off about a quarter of the company's market capitalization when shares began trading.

Investors in Hemispherx were a tad kinder: its share price decreased 10 percent for the day it announced its restatement after dropping nearly 14 percent at one time. On Monday, the $166 million market cap biopharmaceutical company admitted that an incorrect accounting principle was applied to certain debentures and warrants issued between March 2003 and August 2005.

Printer Friendly | Permalink |  | Top
 

Home » Discuss » Latest Breaking News Donate to DU

Powered by DCForum+ Version 1.1 Copyright 1997-2002 DCScripts.com
Software has been extensively modified by the DU administrators


Important Notices: By participating on this discussion board, visitors agree to abide by the rules outlined on our Rules page. Messages posted on the Democratic Underground Discussion Forums are the opinions of the individuals who post them, and do not necessarily represent the opinions of Democratic Underground, LLC.

Home  |  Discussion Forums  |  Journals |  Store  |  Donate

About DU  |  Contact Us  |  Privacy Policy

Got a message for Democratic Underground? Click here to send us a message.

© 2001 - 2011 Democratic Underground, LLC